Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1605: Atezolizumab in BCG-Unresponsive NMIBC
NCT02844816Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in bladder cancer, sponsored by National Cancer Institute. Started Mar 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02844816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844816.